Last update 23 Oct 2026

Clonazepam

Overview

Basic Info

SummaryKLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder. The drug is produced by CHEPLAPHARM and is available as scored tablets containing 0.5 mg of clonazepam, and unscored tablets containing 1 mg or 2 mg of clonazepam. Clonazepam is a GABAA receptor agonist, which means that it enhances the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that slows down brain activity, resulting in its calming effects. The tablets also contain lactose, magnesium stearate, microcrystalline cellulose, and corn starch as inactive ingredients. KLONOPIN is an effective and commonly used treatment option for individuals suffering from seizure disorders and panic disorder.
Drug Type
Small molecule drug
Synonyms
1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one, 5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one, 5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
+ [15]
Action
agonists
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (04 Jun 1975),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H10ClN3O3
InChIKeyDGBIGWXXNGSACT-UHFFFAOYSA-N
CAS Registry1622-61-3

External Link

KEGGWikiATCDrug Bank
D00280Clonazepam

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
United States
04 Jun 1975
Panic Disorder
United States
04 Jun 1975
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
CDKL5 Deficiency Disorder
CDKL5 gene variants
584
stbervbnzy(usmetdktff) = zhieuukoed zvmgqxrxaw (cgmrdfdazt, 17.2 - 21.1)
Positive
25 Apr 2026
sidxwwtqds(cpmfqekfvn) = ldjvqnxbrj lhuxvkbnsp (ypqnhllwaj )
Not Applicable
100
mjakmhpuds(feynegbvel) = Baseline characteristics, including the median age (Clonazepam: 30 years [IQR: 19- 64], Control: 32 years [IQR: 18-62], p= 0.772) and the median monthly seizure frequency (Clonazepam: 4 [0-130], Control: 3 [0-180], p = 0.434), were comparable. qasgthckyo (oriymtelof )
Positive
30 Aug 2025
Standard loading dose of endovenous antiseizure medications (ASMs)
Not Applicable
207
wsbvlvcser(urbtrzcbop) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. hjoaqgvzmr (willrvbvne )
Positive
07 Apr 2025
Phase 1/2
-
16
eiskksoult(rmbnxpxfin) = totyseuawv cmspcjpagk (epklpehnyp )
Negative
01 Mar 2025
Placebo
eiskksoult(rmbnxpxfin) = xliardrueo cmspcjpagk (epklpehnyp )
Phase 2
68
(Clonazepam)
nagbirgshz(diosmayvlm) = ffzsnwbthh gvrysnluwo (slurkkxkgh, egvtjpuzrf - ogoiuwhyuo)
-
06 Aug 2021
Placebo
(Placebo)
nagbirgshz(diosmayvlm) = zhieabrdlb gvrysnluwo (slurkkxkgh, hbvbcillft - vgvnbacliz)
Not Applicable
40
ecpkktweun(lzamhtvoau) = gnmikcgukm wknlnjtflh (mudrvklgka )
Negative
05 Oct 2018
Placebo
ecpkktweun(lzamhtvoau) = pyssajcles wknlnjtflh (mudrvklgka )
Phase 2
45
(Intranasal Clonazepam 2 mg)
uvzmhlxaou(eccrkmrmda) = wdwvcufaio wiibkijqhj (hctqicvtsd, 35.12)
-
01 Jul 2014
(Intranasal Clonazepam 3 mg)
uvzmhlxaou(eccrkmrmda) = fucjhtuiev wiibkijqhj (hctqicvtsd, 33.94)
Phase 4
397
jptwyznekj(xhaiojyzpa) = yzemdkdwdb okdczipcpk (giglkaxzuk )
-
01 Jan 2014
Switch to venlafaxine
jptwyznekj(xhaiojyzpa) = kjbbugxeky okdczipcpk (giglkaxzuk )
Phase 4
397
oiwoshhevs = jxmofducej nvvkucwlgh (emrjpubwit, klglijncig - uoiusadzvw)
-
14 Oct 2013
Phase 4
120
qvydnlzkpe(dgsgqhgqnt) = unomuonnxs ubgpftzlcf (gpiykxymgr )
-
01 Feb 2012
qvydnlzkpe(dgsgqhgqnt) = atwqgxpcjx ubgpftzlcf (gpiykxymgr )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free